Clementia Pharmaceuticals is a clinical stage biopharmaceutical company that is developing disease-modifying treatments for patients suffering from debilitating bone and other diseases with high unmet medical need. Co.'s lead product candidate, palovarotene, is an oral small molecule that binds and activates retinoic acid receptor gamma (an RARg agonist), and has shown potent activity in preventing abnormal new bone formation as well as scar tissue formation (or fibrosis) in a variety of tissues in animal models. Co. is developing palovarotene for the treatment of Fibrodysplasia Ossificans Progressiva (FOP) and Multiple Osteochondroma (MO). We show 3 historical shares outstanding datapoints in our CMTA shares outstanding history coverage, used to compute CMTA market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing CMTA market cap history over the course of time is important for investors
interested in comparing CMTA's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of CMTA versus a peer is one thing; comparing
CMTA market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like CMTA can fluctuate over the course of history.
With this page we aim to empower investors researching CMTA by allowing them to research the CMTA market cap history. |
Free CMTA Email Alerts:
Video: The Importance of Market Cap
